Noninfectious Inflammatory Response following Intravitreal Bevacizumab Injections: Description of a Cluster of Cases in Two Centers and a Review of the Literature

Ophthalmologica. 2018;240(3):163-166. doi: 10.1159/000492681. Epub 2018 Aug 31.

Abstract

Purpose: To report a cluster of high incidence of noninfectious inflammatory reaction shortly after bevacizumab injection.

Methods: Data were collected from medical records of consecutive patients who underwent bevacizumab injections and presented with acute uveitis within 1-4 days.

Results: All 7 patients were injected intravitreally with bevacizumab from different batches and presented with visual deterioration. One patient with anterior uveitis complained of pain. None had hypopyon. Three patients with vitritis underwent a vitreous tap with an intravitreal injection of vancomycin and ceftazidime for possible infectious endophthalmitis. All patients received intensive topical antibiotic drops and steroids, and the intraocular inflammation resolved completely within 1 month. Five patients continued to receive bevacizumab injections without recurrent episodes.

Conclusions: Our series demonstrates an incidence of noninfectious inflammatory reaction shortly after bevacizumab injection that is higher than that reported in the literature. The cause is more likely the preparation process in the same compounding pharmacy.

Keywords: Bevacizumab; Noninfectious inflammatory reaction; Preparation process; Uveitic reaction.

Publication types

  • Multicenter Study
  • Review

MeSH terms

  • Acute Disease
  • Administration, Ophthalmic
  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors / adverse effects*
  • Anti-Bacterial Agents / therapeutic use
  • Bevacizumab / adverse effects*
  • Cluster Analysis
  • Female
  • Humans
  • Incidence
  • Inflammation / diagnosis
  • Inflammation / drug therapy
  • Inflammation / epidemiology
  • Intravitreal Injections
  • Macular Degeneration / drug therapy
  • Male
  • Ophthalmic Solutions
  • Retinal Vein Occlusion / drug therapy
  • Uveitis / diagnosis
  • Uveitis / drug therapy
  • Uveitis / epidemiology*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • Angiogenesis Inhibitors
  • Anti-Bacterial Agents
  • Ophthalmic Solutions
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab